Knowledge Library

High-Quality and Cost-Effective Plasmid Platform

In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

Resource Type: Webinar
Resource Topic: Advanced Testing Clinical & Commercial Manufacturing

VIEW

Lentiviral Vector Platform Generation: Increase titer and yield with greater predictability

The field of gene and cell therapies expand rapidly in the past several years. Lentiviral vectors have been in a great demand as gene carriers in this field, especially for ex vivo gene therapies. However, the large scale lentiviral vector production still remains significant challenges. WuXi Advanced Therapies have experience working with Lentivirus since 2015 …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Increasing Predictability with AAV Platform Technologies

AAV vectors are widely used in gene therapy, largely because they do not become integrated into the patient’s DNA and are safe from an immunogenicity perspective. AAVs also offer great versatility, with different targets possible using different serotypes. Relative to other vectors, AAVs are also generally produced at higher titers, which reduces costs. In addition, …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Innovations in the Manufacturing of Cell and Gene Therapies

  Advancements in next-generation cell and gene therapies are fulfilling the promise of personalized medicine and attempting to cure and heal patients. Multiple approved products have been launched in global markets and the number of clinical trials continues to grow. Developing innovative advanced therapies is one of the biopharmaceutical industry’s greatest opportunities to dramatically improve …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Introducing High-Quality and Cost-Effective R&D and GMP Plasmid DNA

WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmid for use in a wide variety of R&D, clinical, and  commercial bioprocessing applications, with an integrated platform of capabilities that allows for a seamless single-source approach …Read More >

Resource Type: White Paper
Resource Topic: Clinical & Commercial Manufacturing

VIEW